Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 279 M
EBIT 2016 -101 M
Net income 2016 -135 M
Finance 2016 64,3 M
Yield 2016 -
Sales 2017 353 M
EBIT 2017 -66,5 M
Net income 2017 -102 M
Finance 2017 97,7 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 20,2x
EV / Sales2017 15,8x
Capitalization 5 693 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates its business through the Ionis Core and Akea Therapeutics segments.The Ionis Core segment involves a a novel drug discovery platform generate a broad pipeline of drugs.The Akea... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
01/19 IONIS PHARMACEUTICALS : Significantly Improves Upon 2016 Financial Guidance
01/13 IONIS PHARMACEUTICALS : New Data Show SPINRAZA™ (nusinersen) Significantly..
01/12 IONIS PHARMACEUTICALS : Reports Positive Data from Phase 2 Study of IONIS-GCGR R..
01/12 IONIS PHARMACEUTICALS : and Akcea Enter into Strategic Collaboration with Global..
01/10 IONIS PHARMACEUTICALS : Novartis invests in Ionis' therapies to reduce cardiovas..
01/10 IONIS PHARMACEUTICALS, INC. (NASDAQ : IONS) Files An 8-K Entry into a Material D..
01/09 IONIS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Unregist..
01/09 IONIS PHARMACEUTICALS : Novartis invests in next generation therapies to reduce ..
01/08 IONIS PHARMACEUTICALS, INC. (NASDAQ : IONS) Files An 8-K Results of Operations a..
01/08 IONIS PHARMACEUTICALS : and Akcea Enter into Strategic Collaboration with Global..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 47,2 $
Spread / Average Target 0,49%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%5 693
INCYTE CORPORATION17.21%22 083
QUINTILES IMS HOLDINGS..0.07%18 734
CELLTRION, INC.--.--%10 483
LONZA GROUP AG4.14%9 679
ALKERMES PLC0.72%8 507
More Results